Literature DB >> 2734331

Blockade of 5-hydroxytryptamine3 receptors prevents cisplatin-induced but not motion- or xylazine-induced emesis in the cat.

J B Lucot1.   

Abstract

5-Hydroxytryptamine3 antagonists have been reported to prevent emesis elicited by cisplatin and radiation. This study investigated the possibility that drugs with this mechanism of action may be useful in preventing emesis elicited by other stimuli. The drugs ICS 205-930 (0.1 and 1.0 mg/kg) and MDL 72222 (0.1 and 1.0 mg/kg) were administered SC to cats before challenging them with either provocative motion or an emetic dose of xylazine. In no instance was a significant reduction in emesis evident. Zacopride was also administered before motion testing (0.01 to 10.0 mg/kg) and found to not have efficacy. To test the possibility that species or route of administration were factors in the negative results, 1.0 mg/kg of ICS 205-930 was administered SC before IV infusion of 7.5 mg/kg of cisplatin. There was a total suppression of emesis for the duration of the six-hour observation periods. This result verifies other work which found 5-hydroxytryptamine3 antagonists to be effective in preventing emesis elicited by cancer chemotherapeutic treatments. However, there is no evidence that they are effective in other syndromes, such as motion sickness and xylazine-induced emesis.

Entities:  

Keywords:  NASA Discipline Neuroscience; NASA Discipline Number 16-10; NASA Program Biomedical Research; Non-NASA Center

Mesh:

Substances:

Year:  1989        PMID: 2734331     DOI: 10.1016/0091-3057(89)90235-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  10 in total

1.  Characterization of the 5-hydroxytryptamine receptors mediating contraction in the intestine of Suncus murinus.

Authors:  F A Javid; R J Naylor
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 2.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

3.  Topographical distribution of 5-HT3 receptor recognition sites in the ferret brain stem.

Authors:  J M Barnes; N M Barnes; B Costall; I L Naylor; R J Naylor; J A Rudd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

Review 4.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

5.  The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.

Authors:  C J Gardner; D J Twissell; T J Dale; J D Gale; C C Jordan; G J Kilpatrick; C Bountra; P Ward
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

6.  Cisplatin-induced early and delayed emesis in the pigeon.

Authors:  S Tanihata; H Igarashi; M Suzuki; T Uchiyama
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 7.  Ondansetron. Therapeutic use as an antiemetic.

Authors:  R J Milne; R C Heel
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 8.  Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic.

Authors:  C R Lee; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

9.  Blockade of motion- and cisplatin-induced emesis by a 5-HT2 receptor agonist in Suncus murinus.

Authors:  F Okada; H Saito; N Matsuki
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

10.  Ondansetron and promethazine have differential effects on hypothermic responses to lithium chloride administration and to provocative motion in rats.

Authors:  Drielle D Guimaraes; Paul L R Andrews; John A Rudd; Valdir A Braga; Eugene Nalivaiko
Journal:  Temperature (Austin)       Date:  2015-10-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.